Novo Nordisk Releases New CagriSema Analysis Showing 25.4% Weight Loss Among Early Responders

A new post hoc analysis from Novo Nordisk found that adults who responded early to investigational CagriSema averaged 25.4% weight loss by week 68, while delayed responders still posted substantial reductions.

Robert
Written by Robert Paulsen
Published
Share

Novo Nordisk on Sunday released a new analysis of its late-stage CagriSema obesity trial showing that participants who responded early to treatment went on to lose an average of 25.4% of their body weight by week 68. The company said the finding came from a post hoc review of REDEFINE 1, a phase 3 study of the investigational fixed-dose combination of cagrilintide and semaglutide.

The result is more specific than a headline number might suggest. Novo defined early responders as adults who had already lost at least 5% of their body weight by week 8. In that subgroup, average observed weight loss reached 25.4% at week 68. Participants classified as delayed responders, meaning they had lost less than 5% by week 8, still recorded average observed weight loss of 17.8% by week 68.

Novo disclosed the new findings in an official announcement tied to presentations at ObesityWeek 2026 in Washington. The company also said the analysis was post hoc and hypothesis-generating, an important distinction because such work can offer useful signals about treatment patterns without carrying the same weight as the trial’s pre-specified primary endpoints.

Early-response split adds detail to the REDEFINE 1 results

According to Novo, 67.8% of CagriSema-treated participants in the analysis were early responders. The company said those patients lost an average of 7.8% by week 8 and 25.4% by week 68. Delayed responders lost an average of 3.4% by week 8 and 17.8% by week 68. The table released by Novo listed 1,367 early responders and 649 delayed responders.

The company also broke down how those week-68 outcomes were distributed. Among early responders, 73.3% achieved at least 20% weight loss by week 68, compared with 37.2% of delayed responders. Another 16.1% of early responders and 23.8% of delayed responders fell into the 15% to under 20% range. Only 0.3% of the early-response group finished week 68 with less than 5% weight loss, versus 3.6% of delayed responders.

Novo said women were more likely to be early responders than delayed responders, with rates of 71.8% and 59.5%, respectively. The company did not frame that split as a prescribing rule, and an outside investigator quoted in the release emphasized that the analysis should not be treated as a basis for changing clinical decision-making. Instead, the main takeaway is that people on the drug candidate did not follow one single weight-loss path, even when many eventually posted large reductions.

That nuance matters because CagriSema has drawn close attention as Novo tries to extend its position in obesity treatment beyond semaglutide alone. Investors, clinicians and payers are all trying to understand not only the headline efficacy numbers, but also how quickly patients may respond and whether early progress says anything useful about longer-term outcomes.

Second post hoc analysis focused on physical function

The company paired the early-responder analysis with another post hoc look at patient-reported outcomes in REDEFINE 1. Novo said 73.1% of adults treated with investigational CagriSema reported a meaningful improvement in physical function at 68 weeks, compared with 49.1% for placebo under the efficacy estimand. That analysis was also presented at ObesityWeek 2026.

Both updates build on a study that Novo describes as a 68-week, double-blind, placebo- and active-controlled phase 3 trial in 3,417 adults with obesity or overweight plus at least one comorbidity and without type 2 diabetes. A listing for REDEFINE 1 on ClinicalTrials.gov shows the trial comparing once-weekly CagriSema against placebo, cagrilintide and semaglutide.

Even with strong weight-loss numbers, safety and tolerability remain central to how regulators and physicians assess a medicine. Novo said adverse events in REDEFINE 1 were mainly gastrointestinal and mostly transient and mild to moderate. The release listed gastrointestinal adverse events in 79.6% of the CagriSema group and 39.9% of the placebo group. Nausea, constipation and vomiting were the most frequently reported categories. Discontinuations due to adverse events occurred in 5.9% of participants receiving CagriSema, compared with 3.5% for placebo.

Those details help explain why the new responder analysis is informative but not self-contained. Early weight-loss patterns may be clinically interesting, yet any regulatory or commercial case for the drug still depends on the full balance of efficacy, safety, tolerability and durability across the broader development program.

CagriSema is still investigational as approval decision nears

Novo said it filed a New Drug Application with the U.S. Food and Drug Administration in December 2025 for CagriSema 2.4 mg / 2.4 mg as a weight-management treatment. The company added that a decision is expected in the fourth quarter of 2026. It also stated clearly that CagriSema is not approved for use in the United States and that its safety and efficacy have not been established.

That regulatory status is essential context for the latest announcement. Sunday’s update was not an approval decision, a label expansion or a new primary-endpoint readout. It was a deeper cut of existing phase 3 data designed to show how different patients progressed over time in REDEFINE 1. Because the work is post hoc, it should be read as a way to refine expectations and generate further questions rather than as definitive evidence for a new treatment claim.

The release also lands just one day after Novo published separate phase 3 results from REDEFINE 9, another CagriSema study that evaluated lower doses. Taken together, the back-to-back announcements show the company continuing to broaden the evidence base around the candidate ahead of a possible regulatory decision. That strategy matters because the obesity market has become more competitive, and drugmakers increasingly need to demonstrate not only average weight loss but also consistency, tolerability and real-world usefulness across different patient groups.

For now, the new 25.4% figure stands as a more granular signal from the REDEFINE 1 dataset, not a replacement for the trial’s broader findings. The next concrete milestone remains the FDA’s decision on Novo’s application, which the company still expects in the fourth quarter.

Robert

About the author

Robert Paulsen

Personal Finance Writer

Robert Paulsen writes about personal finance choices involving spending, saving, debt, insurance and long-term goals. With more than a decade of financial-writing experience, he focuses on the trade-offs that determine whether a common rule actually suits a household.

View author profile